BCYC vs BIOA: fair value comparison
Bicycle Therapeutics plc and BioAge Labs, Inc. · Updated 2026-10-19
BCYC has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. BIOA has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, BCYC currently ranks higher by quality score.
| BCYC | BIOA | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $3.46 | $4.84 |
| 12-month range | $3.38–$8.76 | $4.84–$25.10 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #178 of 301 Healthcare | #180 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Low |
| Margin trend | Expanding | Expanding |
| Revenue growth | Declining | — |
| RSI zone | Neutral | Oversold |
| 50/200-day trend | Downtrend | Mixed |
| 52-week position | The bottom quarter | The bottom quarter |
Full single-stock breakdowns: BCYC fair value analysis · BIOA fair value analysis